The Medical Letter on Drugs and Therapeutics
Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the combined use of the programmed death receptor-1 (PD-1) blocking antibody nivolumab (Opdivo)1 and the anti-CLA-4 antibody ipilimumab (Yervoy)2 for treatment of BRAF V600 wild-type unresectable or metastatic melanoma. This is the first immunotherapy combination to be approved for treatment of any type of cancer.

CLINICAL STUDIES — Approval of nivolumab plus ipilimumab was based on the results of a double-blind trial in 142 patients with previously untreated unresectable or metastatic melanoma (109 patients with BRAF V600 wild-type tumors were included in the primary efficacy analysis); the combination significantly improved the objective response rate (61% vs 11%) and median progression-free survival (not yet reached vs 4.4 months) compared to ipilimumab alone. A complete response was achieved in 22% ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma
Article code: 1483e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian